Posted by Michael Wonder on 18 Apr 2024
Lumicell’s cutting-edge imaging platform receives historic FDA approval to illuminate residual breast cancer
18 April 2024 - Lumisight and Lumicell DVS previously received FDA fast track and breakthrough device designations, respectively.
Lumicell today announced the US FDA approved the company’s new drug application for its Lumisight (pegulicianine) optical imaging agent and its premarket approval application for Lumicell Direct Visualization System, together referred to as LumiSystem.
